PMID- 21286344
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1936-0541 (Electronic)
IS  - 1936-0533 (Print)
IS  - 1936-0533 (Linking)
VI  - 4
IP  - 4
DP  - 2010 Aug 9
TI  - Comparison of adverse effects related to pegylated interferon-based therapy for 
      patients with chronic hepatitis B and chronic hepatitis C in Taiwan.
PG  - 732-40
LID - 10.1007/s12072-010-9208-0 [doi]
AB  - PURPOSE: Pegylated interferon (Peg-IFN)-based therapy is effective in treating 
      chronic hepatitis B (CHB) and C (CHC) but frequently induces adverse events 
      (AEs). This study was conducted to compare the incidence of Peg-IFN-based 
      therapy-associated AEs in Taiwanese patients with CHB and CHC. METHODS: Fifty-six 
      patients with CHB and 103 age-, sex- and treatment duration-matched patients with 
      CHC were enrolled. Patients with CHB were treated with Peg-IFN-alpha-2a 180 mug/week 
      for 24 weeks (HBeAg(+), n = 31) or 48 weeks (HBeAg(-), n = 25); patients with CHC 
      were treated with Peg-IFN-alpha-2a 180 mug/week plus ribavirin 1,000-1,200 mg/day for 
      24 weeks (genotype 2/3, n = 57) or 48 weeks (genotype 1, n = 46). RESULTS: 
      Significantly higher incidences of Peg-IFN-related AEs, especially 
      neuropsychiatric symptoms, and ribavirin-associated skin manifestations were 
      observed in patients with CHC compared with those with CHB, with either the 24- 
      or 48-week regimen. Frequencies of laboratory abnormalities, except for anemia, 
      were comparable in both groups. Neither group showed overt hepatic 
      decompensation. Frequency of dose reduction was similar between the groups. 
      Substantially higher rates of early termination and severe AEs were observed in 
      patients with CHC. CONCLUSIONS: Patients with CHB treated with Peg-IFN had fewer 
      AEs than patients with CHC treated with Peg-IFN/ribavirin. All patients were 
      treated safely.
FAU - Yang, Jeng-Fu
AU  - Yang JF
FAU - Kao, Yi-Hui
AU  - Kao YH
FAU - Dai, Chia-Yen
AU  - Dai CY
FAU - Huang, Jee-Fu
AU  - Huang JF
FAU - Hsieh, Ming-Yen
AU  - Hsieh MY
FAU - Lin, Zu-Yau
AU  - Lin ZY
FAU - Chen, Shinn-Cherng
AU  - Chen SC
FAU - Hsieh, Ming-Yuh
AU  - Hsieh MY
FAU - Wang, Liang-Yen
AU  - Wang LY
FAU - Chuang, Wan-Long
AU  - Chuang WL
FAU - Yu, Ming-Lung
AU  - Yu ML
LA  - eng
PT  - Journal Article
DEP - 20100809
PL  - United States
TA  - Hepatol Int
JT  - Hepatology international
JID - 101304009
PMC - PMC2994613
OTO - NOTNLM
OT  - Adverse events (AEs)
OT  - CHB
OT  - CHC
OT  - Peg-IFN-based therapy
OT  - Safety profile
EDAT- 2011/02/03 06:00
MHDA- 2011/02/03 06:01
PMCR- 2010/08/09
CRDT- 2011/02/03 06:00
PHST- 2009/08/20 00:00 [received]
PHST- 2010/07/21 00:00 [accepted]
PHST- 2011/02/03 06:00 [entrez]
PHST- 2011/02/03 06:00 [pubmed]
PHST- 2011/02/03 06:01 [medline]
PHST- 2010/08/09 00:00 [pmc-release]
AID - 9208 [pii]
AID - 10.1007/s12072-010-9208-0 [doi]
PST - epublish
SO  - Hepatol Int. 2010 Aug 9;4(4):732-40. doi: 10.1007/s12072-010-9208-0.